Ramon GB Bonegio, MD
Assistant Professor
Boston University School of Medicine
Dept of Medicine
Nephrology Section

MD, University of the Witwatersrand



I am a physician- scientist who trained in internal medicine and nephrology at the University of the Witwatersrand in South Africa before moving to Boston to complete a nephrology fellowship and PhD in molecular medicine. Since 2003 I have focused my clinical activities on the diagnosis and management of patients with lupus-nephritis and immune complex glomerulonephritis and in 2011 joined with Dr. Robert Lafyatis (rheumatology), Dr. Michael York (rheumatology), Dr Hanni Menn-Josephy (nephrology), Dr. Ian Rifkin (nephrology), and Dr. Christina Lam (dermatology) to establish the Boston Medical Center Lupus Program which I currently co-direct. Since establishing the Lupus Program, our center has participated in four clinical trials involving lupus patients which has allowed us to develop the infrastructure required for the acquisition of patient informed consents, sample collection and storage, and for the management of the information systems required to maintain a database of relevant clinical characteristics that are linked to each sample.

I have a longstanding interest in autoimmune disease in general and in lupus nephritis in particular and run a basic science laboratory of my own that is funded to investigate the pathobiology of immune-complex glomerulonephritis. We use cell culture systems and mouse models of autoimmunity to define pathways that are required for the development or progression of autoimmunity and use this understanding develop new therapeutics.

My basic science work has given me a unique perspective of the requirements that basic scientists and clinicians have to translate basic science breakthroughs to the clinical arena. In the last two years I have worked with our trial manager Dr Britte Zlatanova to established an autoimmune patient registry at Boston Medical Center that now includes over 100 lupus patients and appropriate control samples. I work in collaboration with several pharmaceutical companies and investigators from Boston University Medical Center, the University of Massachusetts, Pittsburg University, and University of Pennsylvania to share this valuable clinical material in order to develop the understanding the biology of autoimmunity and inflammation in anticipation that this will lead to new therapies that are more effective and less toxic..

Expertise includes: Lupus nephritis, Autoimmune kidney disease, Glomerulonephritis, Toxicity of immunosuppression, Genetics of immune-mediated kidney disease

Active Staff Hospital Privileges
Boston Medical Center
Medicine



2012-2017 NIDDK: Endogenous RNA Ligands For Toll-like Receptors In Immune-Complex Nephritis
2000-2001 Boston University Medical Center: Excellence in Teaching Award


A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of BMS-188667 (Abatacept) or Placebo on a Background of Mycophenolate Mofetil (MMF) and Corticosteroids
08/01/2013 - 07/31/2016 (PI)
Bristol-Myers Squibb

A Multi-center, randomized, double-blind, placebo-controlled study to evaluate the efficacy, safety and tolerability of BIIB023 in subjects with Lupus Nephritis
04/01/2013 - 05/25/2016 (PI)
Biogen Idec


Endogenous RNA Ligands for Toll-like Receptors in Immune-complex Nephritis
07/01/2012 - 06/30/2018 (PI)
NIH-NIDDK
4R01 DK095058-05

Endogenous RNA Ligands for Toll-like Receptors in Immune-complex Nephritis
07/01/2012 - 06/30/2018 (PI)
NIH-NIDDK
5R01 DK095058-04

TULIP D3461C000007
06/14/2016 - 06/14/2018 (PI)
Astrazeneca Pharmaceuticals

A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 3 Study Evaluating the Effica…
11/11/2015 - 11/11/2017 (PI)
Astrazeneca Pharmaceuticals


Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.

  1. Wang Z, Gall JM, Bonegio R, Havasi A, Illanes K, Schwartz JH, Borkan SC. Correction for Wang et al., "Nucleophosmin, a Critical Bax Cofactor in Ischemia-Induced Cell Death". Mol Cell Biol. 2017 Oct 01; 37(19).View Related Profiles. PMID: 28899998.
  2. Menn-Josephy H, Lee CS, Nolin A, Christov M, Rybin DV, Weinberg JM, Henderson J, Bonegio R, Havasi A. Renal Interstitial Fibrosis: An Imperfect Predictor of Kidney Disease Progression in Some Patient Cohorts. Am J Nephrol. 2016; 44(4):289-299.View Related Profiles. PMID: 27626625.
  3. Bossaller L, Christ A, Pelka K, Nündel K, Chiang PI, Pang C, Mishra N, Busto P, Bonegio RG, Schmidt RE, Latz E, Marshak-Rothstein A. TLR9 Deficiency Leads to Accelerated Renal Disease and Myeloid Lineage Abnormalities in Pristane-Induced Murine Lupus. J Immunol. 2016 Aug 15; 197(4):1044-53.View Related Profiles. PMID: 27354219; DOI: 10.4049/jimmunol.1501943;.
  4. Al-Rabadi L, Ayalon R, Bonegio RG, Ballard JE, Fujii AM, Henderson JM, Salant DJ, Beck LH. Pregnancy in a Patient With Primary Membranous Nephropathy and Circulating Anti-PLA2R Antibodies: A Case Report. Am J Kidney Dis. 2016 May; 67(5):775-8.View Related Profiles. PMID: 26744127; PMCID: PMC4837089; DOI: 10.1053/j.ajkd.2015.10.031;.
  5. Duffau P, Menn-Josephy H, Cuda CM, Dominguez S, Aprahamian TR, Watkins AA, Yasuda K, Monach P, Lafyatis R, Rice LM, Kenneth Haines G, Gravallese EM, Baum R, Richez C, Perlman H, Bonegio RG, Rifkin IR. Promotion of Inflammatory Arthritis by Interferon Regulatory Factor 5 in a Mouse Model. Arthritis Rheumatol. 2015 Dec; 67(12):3146-57.View Related Profiles. PMID: 26315890; PMCID: PMC4661118; DOI: 10.1002/art.39321;.
  6. Watkins AA, Yasuda K, Wilson GE, Aprahamian T, Xie Y, Maganto-Garcia E, Shukla P, Oberlander L, Laskow B, Menn-Josephy H, Wu Y, Duffau P, Fried SK, Lichtman AH, Bonegio RG, Rifkin IR. IRF5 deficiency ameliorates lupus but promotes atherosclerosis and metabolic dysfunction in a mouse model of lupus-associated atherosclerosis. J Immunol. 2015 Feb 15; 194(4):1467-79.View Related Profiles. PMID: 25595782; PMCID: PMC4323680; DOI: 10.4049/jimmunol.1402807;.
  7. Gall JM, Wang Z, Bonegio RG, Havasi A, Liesa M, Vemula P, Borkan SC. Conditional knockout of proximal tubule mitofusin 2 accelerates recovery and improves survival after renal ischemia. J Am Soc Nephrol. 2015 May; 26(5):1092-102.View Related Profiles. PMID: 25201884; PMCID: PMC4413756; DOI: 10.1681/ASN.2014010126;.
  8. Yasuda K, Watkins AA, Kochar GS, Wilson GE, Laskow B, Richez C, Bonegio RG, Rifkin IR. Interferon regulatory factor-5 deficiency ameliorates disease severity in the MRL/lpr mouse model of lupus in the absence of a mutation in DOCK2. PLoS One. 2014; 9(7):e103478.View Related Profiles. PMID: 25076492; PMCID: PMC4116215; DOI: 10.1371/journal.pone.0103478;.
  9. Aprahamian TR, Bonegio RG, Weitzner Z, Gharakhanian R, Rifkin IR. Peroxisome proliferator-activated receptor gamma agonists in the prevention and treatment of murine systemic lupus erythematosus. Immunology. 2014 Jul; 142(3):363-73.View Related Profiles. PMID: 24456224; PMCID: PMC4080952; DOI: 10.1111/imm.12256;.
  10. Watkins AA, Bonegio RG, Rifkin IR. Evaluating the role of nucleic acid antigens in murine models of systemic lupus erythematosus. Methods Mol Biol. 2014; 1169:143-58.View Related Profiles. PMID: 24957237; DOI: 10.1007/978-1-4939-0882-0_14;.
Showing 10 of 34 results. Show More

This graph shows the total number of publications by year, by first, middle/unknown, or last author.

Bar chart showing 34 publications over 15 distinct years, with a maximum of 4 publications in 2009 and 2011 and 2012 and 2014

YearPublications
19881
20011
20022
20041
20051
20062
20094
20101
20114
20124
20133
20144
20153
20162
20171
Contact for Mentoring:


650 Albany St Evans Biomed Research Ctr
Boston MA 02118
Google Map


Bonegio's Networks
Click the "See All" links for more information and interactive visualizations
Concepts
_
Co-Authors
_
Similar People
_
Same Department